glp 1 cardiovascular disease Frontiers Cardiovascular Protective Properties of GLP-1

Hypoglycemia, while less common with tirzepatide alone due to its glucose-dependent mechanism, may occur, particularly in patients taking concurrent medications that affect blood glucose

Looking ahead, the market is expected to continue growing as breakthroughs in novel molecular designs, oral formulations, and dual-target drugs push the boundaries of GLP-1 drug innovation

[DOI] [PubMed] [Google Scholar] 74.Faillie JL, Babai S, Crepin S, Bres V, Laroche ML, Le Louet H, Petit P, Montastruc JL, Hillaire-Buys D French Pharmacovigilance Centers Network

This requires 15.6% yearly revenue growth and about a $120 million earnings increase from $128.4 million today

7.2 Healthcare System Impact Price and Access: Having one more major player (Pfizer) investing in obesity could eventually benefit patients through competition and possibly lower net prices

Prescriptions, procedures, and treatment recommendations are provided only when clinically appropriate after medical review